Similar articles

• Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

  Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Rosen LS, et al. J Clin Oncol. 2003 Aug 15;21(16):3150-7. doi: 10.1200/JCO.2003.04.105. J Clin Oncol. 2003. PMID: 12915606 Clinical Trial.
• Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

  Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Smith MR, et al. J Urol. 2003 Jun;169(6):2008-12. doi: 10.1097/01.ju.0000063820.94994.95. J Urol. 2003. PMID: 12771706 Clinical Trial.
• Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.

  Saad F, McKiernan J, Eastham J. Saad F, et al. Urol Oncol. 2006 Jan-Feb;24(1):4-12. doi: 10.1016/j.urolonc.2005.06.020. Urol Oncol. 2006. PMID: 16414486 Review.
• Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

  Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Rosen LS, et al. Cancer J. 2001 Sep-Oct;7(5):377-87. Cancer J. 2001. PMID: 11693896 Clinical Trial.
• Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.

  Saad F, Colombel M. Saad F, et al. Expert Rev Anticancer Ther. 2010 Dec;10(12):1991-2002. doi: 10.1586/era.10.191. Expert Rev Anticancer Ther. 2010. PMID: 21110764 Review.